Cytokinetics may walk a lonely road to market with tarnished heart med omecamtiv after last partner bows out
Once flush with partners for heart failure drug omecamtiv mecarbil, Cytokinetics watched its longtime ally Amgen flee last month over weak data from a Phase III trial. Now, Cytokinetics’ last running mate is hitting the exit — leaving omecamtiv on an uncertain path to market.
Les Laboratoires Servier and Institut de Recherches Internationales Servier is pulling out of a sublicense agreement for omecamtiv that it struck with Amgen back in 2016. The news comes exactly one month after Amgen unveiled its own plans to walk away in May 2021 from a 14-year alliance for omecamtiv and the tens of millions it spent developing the controversial drug, which it said “did not meet the high bar we had set for the program.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
